Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes

被引：0
|
作者：
Boris Kovatchev
Zhaoling Meng
Anna M. G. Cali
Riccardo Perfetti
Marc D. Breton
机构：
[1] University of Virginia,Center for Diabetes Technology
[2] Sanofi,undefined
[3] Sanofi,undefined
来源：
Diabetes Therapy | 2020年 / 11卷
关键词：
Basal insulin; Glycaemic variability; Hypoglycaemia; Insulin glargine; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1293 / 1302
页数：9
相关论文
共 50 条
  • [1] Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes
    Kovatchev, Boris
    Meng, Zhaoling
    Cali, Anna M. G.
    Perfetti, Riccardo
    Breton, Marc D.
    DIABETES THERAPY, 2020, 11 (06) : 1293 - 1302
  • [2] Glycaemic variability and risk for hypoglycaemia on insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes
    Kovatchev, B.
    Meng, Z.
    Breton, M.
    Leroy, B.
    Cali, A.
    Perfetti, R.
    DIABETOLOGIA, 2017, 60 : S36 - S37
  • [3] COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CROATIA
    Bogdanovic, M.
    Fournier, M.
    Vitezic, D.
    VALUE IN HEALTH, 2018, 21 : S131 - S132
  • [4] COST-UTILITY EVALUATION OF INSULIN GLARGINE (300 U/ML) VERSUS INSULIN GLARGINE (100 U/ML) AND INSULIN DEGLUDEC (100 U/ML) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN SLOVENIA
    Bogdanovic, M.
    Krnel, Rados S.
    Foumier, M.
    VALUE IN HEALTH, 2017, 20 (09) : A481 - A481
  • [5] COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN BULGARIA
    Bogdanovic, M.
    Mihajlovic, J.
    Fournier, M.
    VALUE IN HEALTH, 2018, 21 : S133 - S133
  • [6] Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
    Steinstraesser, A.
    Schmidt, R.
    Bergmann, K.
    Dahmen, R.
    Becker, R. H. A.
    DIABETES OBESITY & METABOLISM, 2014, 16 (09): : 873 - 876
  • [7] Comparison of pharmacodynamics between insulin glargine 100 U/mL and insulin glargine 300 U/mL in healthy cats
    Saini, N. K.
    Wasik, B.
    Pires, J.
    Leale, D. M.
    Quach, N.
    Culp, W. T. N.
    Samms, R. J.
    Johnson, A. E.
    Owens, J. G.
    Gilor, C.
    DOMESTIC ANIMAL ENDOCRINOLOGY, 2021, 75
  • [8] Improved Glycemic Control with Insulin Glargine 300 U/mL vs. Glargine 100 U/mL in Type 1 Diabetes
    Paola, Lucidi
    Cioli, Patrizia
    Candeloro, Paola
    Andreoli, Anna Marinelli
    Bolli, Geremia B.
    Fanelli, Carmine G.
    Porcellati, Francesca
    DIABETES, 2020, 69
  • [9] Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial
    Bolli, Geremia B.
    Cheng, Alice
    Charbonnel, Bernard
    Aroda, Vanita R.
    Westerbacka, Jukka
    Bosnyak, Zsolt
    Boelle-Le Corfec, Emmanuelle
    Rosenstock, Julio
    DIABETES OBESITY & METABOLISM, 2021, 23 (07): : 1588 - 1593
  • [10] The efficacy of switching from Insulin Glargine 100 U/mL (Gla-100) to Insulin Glargine 300 U/mL (Gla-300) in patients with type 2 diabetes mellitus
    Yang, K. -H.
    Tseng, C. -T.
    Chen, L. -C.
    Chen, P. -C.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 310 - 310
12345